A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities
Open accessThe DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Abstract
Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple agents targeting both canonical and the β-catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [119]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · cited 2×
“For example, genetic mutations of Wnt signaling in colorectal cancer (CRC) are observed in more than 90% of patients and are well-known cancer-driving alterations [25,26].”
BackgroundMutations affecting segment number and polarity in Drosophila
Nüsslein-Volhard, C., & Wieschaus, E. (1980) · Nature · doi:10.1038/287795a0 · Cited by 4,370
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Crypt stem cells as the cells-of-origin of intestinal cancer
Barker, N., Ridgway, R. A., van Es, J. H., van de Wetering, M., Begthel, H., van den Born, M., Danenberg, E., Clarke, A. R., Sansom, O. J., & Clevers, H. (2009) · Nature · doi:10.1038/nature07602 · Cited by 2,166
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Huang, S.-M. A., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009) · Nature · doi:10.1038/nature08356 · Cited by 2,037
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Nusse, R., & Varmus, H. E. (1982) · Cell · doi:10.1016/0092-8674(82)90409-3 · Cited by 1,863 · cited 1×
“Concurrently, Int-1, a mammalian wingless homolog, was identified as a driver gene for malignancy when its transcriptional activation was induced by the murine mammary tumor virus [2].”
BackgroundGarzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction
Glinka, A., Wu, W., Delius, H., Monaghan, A. P., Blumenstock, C., & Niehrs, C. (1998) · Nature · doi:10.1038/34848 · Cited by 1,608
The complex world of WNT receptor signalling
Niehrs, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3470 · Cited by 1,492 · cited 5×
“Upon Wnt ligand stimulation (Wnt-on status), AXIN binds to the phosphorylated cytoplasmic tail of LRP5/6 and the FZD receptor adapter Disheveled (Dvl) [3,8].”
BackgroundInfluentialCaught up in a Wnt storm: Wnt signaling in cancer
Giles, R. H., van Es, J. H., & Clevers, H. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00005-2 · Cited by 1,482 · cited 4×
“In colorectal cancer (CRC), the loss-of-mutation of APC and the activating mutation of CTNNB1 are frequently observed [26,27].”
BackgroundInfluentialSmall molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C.-W., Wei, S., Hao, W., Kilgore, J., Williams, N. S., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.137 · Cited by 1,383
An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control
Clevers, H., Loh, K. M., & Nusse, R. (2014) · Science · doi:10.1126/science.1248012 · Cited by 1,364 · cited 2×
“Different combinations of Wnt ligands and their receptors/co-receptors operate in various physiological contexts [6].”
BackgroundLgr5 homologues associate with Wnt receptors and mediate R-spondin signalling
de Lau, W., Barker, N., Low, T. Y., Koo, B.-K., Li, V. S. W., Teunissen, H., Kujala, P., Haegebarth, A., Peters, P. J., van de Wetering, M., et al. (2011) · Nature · doi:10.1038/nature10337 · Cited by 1,272
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Lineage Tracing Reveals Lgr5 + Stem Cell Activity in Mouse Intestinal Adenomas
Schepers, A. G., Snippert, H. J., Stange, D. E., van den Born, M., van Es, J. H., van de Wetering, M., & Clevers, H. (2012) · Science · doi:10.1126/science.1224676 · Cited by 1,072
Wang, K., Yuen, S. T., Xu, J., Lee, S. P., Yan, H. H. N., Shi, S. T., Siu, H. C., Deng, S., Chu, K. M., Law, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2983 · Cited by 1,045 · cited 1×
“6% of the MSI (microsatellite instable) subtype (~80% of patients) and were considered key driver mutations [29,30].”
BackgroundCan we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Bonci, D., Coppola, V., Musumeci, M., Addario, A., Giuffrida, R., Memeo, L., D'Urso, L., Pagliuca, A., Biffoni, M., Labbaye, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1880 · Cited by 989
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Koo, B.-K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., van Es, J. H., Mohammed, S., Heck, A. J. R., Maurice, M. M., et al. (2012) · Nature · doi:10.1038/nature11308 · Cited by 980 · cited 1×
“Conversely, secreted ligands, R-spondins (RSPOs 1-4), serve as Wnt signaling enhancers [11,12].”
BackgroundZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., Lei, H., Mickanin, C., Liu, D., Ruffner, H., et al. (2012) · Nature · doi:10.1038/nature11019 · Cited by 972 · cited 1×
“Conversely, secreted ligands, R-spondins (RSPOs 1-4), serve as Wnt signaling enhancers [11,12].”
BackgroundSatoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960 · cited 1×
“Although the activating mutation of CTNNB1, the most frequent mutation in HCC, does not induce a tumor, the loss-of-APC or Axin1 mutation, both less common in HCC, are able to do so [40,41].”
BackgroundVascular Development in the Retina and Inner Ear
Xu, Q., Wang, Y., Dabdoub, A., Smallwood, P. M., Williams, J., Woods, C., Kelley, M. W., Jiang, L., Tasman, W., Zhang, K., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00216-8 · Cited by 875
Pálmer, H. G., González-Sancho, J. M., Espada, J., Berciano, M. T., Puig, I., Baulida, J., Quintanilla, M., Cano, A., de Herreros, A. G., Lafarga, M., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200102028 · Cited by 802
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743
Wnt/β-catenin signaling in cancers and targeted therapies
Yu, F., Yu, C., Li, F., Zuo, Y., Wang, Y., Yao, L., Wu, C., Wang, C., & Ye, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00701-5 · Cited by 734
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways
Miller, J. R., Hocking, A. M., Brown, J. D., & Moon, R. T. (1999) · Oncogene · doi:10.1038/sj.onc.1203245 · Cited by 691 · cited 1×
“The raised levels of Ca2+ induce the activation of protein kinase C, protein kinase II, and calcineurin [23,24].”
BackgroundA selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Bovolenta, P., Esteve, P., Ruiz, J. M., Cisneros, E., & Lopez-Rios, J. (2008) · Journal of Cell Science · doi:10.1242/jcs.026096 · Cited by 655
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
Stewart, D. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt356 · Cited by 651 · cited 1×
“In non-small cell lung cancer (NSCLC), Wnt ligands (Wnt1, Wnt2, Wnt3, and Wnt5a) and other signaling modules (FZD8, PORCN, and TCF-4) are overexpressed [49].”
Backgroundβ-Catenin destruction complex: insights and questions from a structural perspective
Kimelman, D., & Xu, W. (2006) · Oncogene · doi:10.1038/sj.onc.1210055 · Cited by 628
Gurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 3×
“OMP-18R5 FZD1/2/ 5/7/8 • Solid Tumors • Pancreatic Cancer • Metastatic Breast Cancer Phase 1 (NCT01345201) Phase 1 (NCT01957007) Phase 1 (NCT02005315) Phase 1 (NCT01973309) Canonical [64,65]”
BackgroundPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Hecht, A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1839 · Cited by 607 · cited 3×
“β-catenin also recruits co-activators such as cAMP response element binding protein (CBP) and p300 [20,21].”
BackgroundWnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Orsulic, S., Huber, O., Aberle, H., Arnold, S., & Kemler, R. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.8.1237 · Cited by 534
Wnt/Ca2+ signaling pathway: a brief overview
De, A. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr079 · Cited by 523 · cited 1×
“The raised levels of Ca2+ induce the activation of protein kinase C, protein kinase II, and calcineurin [23,24].”
BackgroundRequirement of Prorenin Receptor and Vacuolar H + -ATPase–Mediated Acidification for Wnt Signaling
Cruciat, C.-M., Ohkawara, B., Acebron, S. P., Karaulanov, E., Reinhard, C., Ingelfinger, D., Boutros, M., & Niehrs, C. (2010) · Science · doi:10.1126/science.1179802 · Cited by 516
Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas
Taniguchi, K., Roberts, L. R., Aderca, I. N., Dong, X., Qian, C., Murphy, L. M., Nagorney, D. M., Burgart, L. J., Roche, P. C., Smith, D. I., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205591 · Cited by 486 · cited 2×
“Approximately 20~25% of CTNNB1, encoding β-catenin, ~10% of AXIN1, and ~3% of AXIN2, are mutated [37,38].”
BackgroundSmall-molecule inhibition of Wnt signaling through activation of casein kinase 1α
Thorne, C. A., Hanson, A. J., Schneider, J., Tahinci, E., Orton, D., Cselenyi, C. S., Jernigan, K. K., Meyers, K. C., Hang, B. I., Waterson, A. G., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.453 · Cited by 485 · cited 2×
“Pyrvinium CK1 • Pancreatic Cancer Phase 1 (NCT05055323) FDA-approved antihelminth Canonical [74]”
BackgroundThe Transcriptional Coactivator Cbp Interacts with β-Catenin to Activate Gene Expression
Takemaru, K.-I., & Moon, R. T. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.149.2.249 · Cited by 473 · cited 4×
“β-catenin also recruits co-activators such as cAMP response element binding protein (CBP) and p300 [20,21].”
BackgroundInfluentialMutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466 · cited 16×
“Pancreatic ductal acinar cell carcinoma (PDAC) exhibits approximately 4~10% mutations in RNF43 and 1% mutations in APC and CTNNB1 [27].”
BackgroundInfluentialHong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445
Niclosamide: Beyond an antihelminthic drug
Chen, W., Mook, R. A., Premont, R. T., & Wang, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.001 · Cited by 444 · cited 1×
“Niclosamide FZD1 • Colon Cancer • Metastatic Prostate-Carcinoma • Acute Myeloid Leukemia Phase 1 (NCT02687009) Phase 1 (NCT03123978) Phase 1 (NCT02532114) Phase 2 (NCT02807805) Phase 1 (NCT05188170) FDA-approved antihelminth Canonical [63]”
BackgroundInactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma
Jiang, X., Hao, H.-X., Growney, J. D., Woolfenden, S., Bottiglio, C., Ng, N., Lu, B., Hsieh, M. H., Bagdasarian, L., Meyer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307218110 · Cited by 414 · cited 3×
“In addition, in patient-derived PDAC cell lines harboring RNF43 mutations, the inhibition of porcupine and FZD5 suppresses the growth of PDAC cells [42,51].”
BackgroundJunge, H. J., Yang, S., Burton, J. B., Paes, K., Shu, X., French, D. M., Costa, M., Rice, D. S., & Ye, W. (2009) · Cell · doi:10.1016/j.cell.2009.07.048 · Cited by 390 · cited 2×
“Though Norrin is a cystine-knot-like growth factor, it activates Wnt signaling by interacting with FZD4, Lrp5/6, and Tetraspanin-12 [14,15].”
BackgroundProffitt, K. D., Madan, B., Ke, Z., Pendharkar, V., Ding, L., Lee, M. A., Hannoush, R. N., & Virshup, D. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2258 · Cited by 382
Wolpin, B. M., Rubinson, D. A., Wang, X., Chan, J. A., Cleary, J. M., Enzinger, P. C., Fuchs, C. S., McCleary, N. J., Meyerhardt, J. A., Ng, K., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0086 · Cited by 374
Wnt signaling pathways meet Rho GTPases
Schlessinger, K., Hall, A., & Tolwinski, N. (2009) · Genes & Development · doi:10.1101/gad.1760809 · Cited by 366 · cited 3×
“In β-catenin-independent signaling, the intracellular downstream signaling of the Wnt/receptor interactions is mediated not by β-catenin but by various cellular signaling modules, such as RAC1-JNK, RHOA-ROCK, and PLC-IP3-Ca2+ (Figure 1).”
BackgroundInfluentialFDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Aartsma-Rus, A., & Krieg, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0657 · Cited by 364
Ji, C. H., Kim, H. Y., Lee, M. J., Heo, A. J., Park, D. Y., Lim, S., Shin, S., Ganipisetti, S., Yang, W. S., Jung, C. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28520-4 · Cited by 350
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341 · cited 3×
“Other PORCN inhibitors, RXC004 (NCT03447470, NCT04907539, and NCT04907851) and ETC-159 (NCT02521844) have also been used in clinical trials [57,59] (Table 1 and Figure 2).”
BackgroundMethodA Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma
Tammela, T., Sanchez-Rivera, F. J., Cetinbas, N. M., Wu, K., Joshi, N. S., Helenius, K., Park, Y., Azimi, R., Kerper, N. R., Wesselhoeft, R. A., et al. (2017) · Nature · doi:10.1038/nature22334 · Cited by 336 · cited 3×
“LGK974 PORCN • Metastatic Colorectal Cancer • Metastatic Head and Neck Squamous Cell Carcinoma • Solid Malignancies Phase 1/2 (NCT02278133) Phase 2 (NCT02649530) Phase 1 (NCT01351103) Canonical/ Non-canonical [3,43,54]”
BackgroundColnot, S., Decaens, T., Niwa-Kawakita, M., Godard, C., Hamard, G., Kahn, A., Giovannini, M., & Perret, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404761101 · Cited by 328 · cited 1×
“Although the activating mutation of CTNNB1, the most frequent mutation in HCC, does not induce a tumor, the loss-of-APC or Axin1 mutation, both less common in HCC, are able to do so [40,41].”
BackgroundWaaler, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., Wilson, S. R., Paulsen, J. E., Pedersen, N. M., Eide, T. J., Machonova, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3336 · Cited by 328
Heo, Y.-A. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 317
A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
Lau, T., Chan, E., Callow, M., Waaler, J., Boggs, J., Blake, R. A., Magnuson, S., Sambrone, A., Schutten, M., Firestein, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4562 · Cited by 316
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306 · cited 2×
“Approximately 20~25% of CTNNB1, encoding β-catenin, ~10% of AXIN1, and ~3% of AXIN2, are mutated [37,38].”
BackgroundSteinhart, Z., Pavlovic, Z., Chandrashekhar, M., Hart, T., Wang, X., Zhang, X., Robitaille, M., Brown, K. R., Jaksani, S., Overmeer, R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4219 · Cited by 297 · cited 1×
“In addition, in patient-derived PDAC cell lines harboring RNF43 mutations, the inhibition of porcupine and FZD5 suppresses the growth of PDAC cells [42,51].”
BackgroundTankyrase-targeted therapeutics: expanding opportunities in the PARP family
Riffell, J. L., Lord, C. J., & Ashworth, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3868 · Cited by 285
Mahalingam, D., Mita, M., Sarantopoulos, J., Wood, L., Amaravadi, R. K., Davis, L. E., Mita, A. C., Curiel, T. J., Espitia, C. M., Nawrocki, S. T., et al. (2014) · Autophagy · doi:10.4161/auto.29231 · Cited by 285
Antibody targeting of E3 ubiquitin ligases for receptor degradation
Marei, H., Tsai, W.-T. K., Kee, Y.-S., Ruiz, K., He, J., Cox, C., Sun, T., Penikalapati, S., Dwivedi, P., Choi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05235-6 · Cited by 273
The Frizzled family of unconventional G-protein-coupled receptors
Schulte, G., & Bryja, V. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.09.001 · Cited by 253 · cited 1×
“These G-protein coupled FZD receptors act as primary Wnt receptors and transduce the Wnt signaling intracellularly [8,9].”
BackgroundTargeted Disruption of the BCL9/β-Catenin Complex Inhibits Oncogenic Wnt Signaling
Takada, K., Zhu, D., Bird, G. H., Sukhdeo, K., Zhao, J.-J., Mani, M., Lemieux, M., Carrasco, D. E., Ryan, J., Horst, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003808 · Cited by 245
Mao, J., Fan, S., Ma, W., Fan, P., Wang, B., Zhang, J., Wang, H., Tang, B., Zhang, Q., Yu, X., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.515 · Cited by 241 · cited 1×
“In addition to mutations in Wnt signaling, the overexpression of Wnt1 and Wnt6 has been observed in gastric cancer [31,32].”
BackgroundOshima, H., Matsunaga, A., Fujimura, T., Tsukamoto, T., Taketo, M. M., & Oshima, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.014 · Cited by 240
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
Corey, D. R. (2017) · Nature Neuroscience · doi:10.1038/nn.4508 · Cited by 240
Boone, B. A., Bahary, N., Zureikat, A. H., Moser, A. J., Normolle, D. P., Wu, W.-C., Singhi, A. D., Bao, P., Bartlett, D. L., Liotta, L. A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4566-4 · Cited by 234
Fujii, N., You, L., Xu, Z., Uematsu, K., Shan, J., He, B., Mikami, I., Edmondson, L. R., Neale, G., Zheng, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2726 · Cited by 232
Expression of Dickkopf genes is strongly reduced in malignant melanoma
Kuphal, S., Lodermeyer, S., Bataille, F., Schuierer, M., Hoang, B. H., & Bosserhoff, A. K. (2006) · Oncogene · doi:10.1038/sj.onc.1209508 · Cited by 225
Ratti, M., Lampis, A., Hahne, J. C., Passalacqua, R., & Valeri, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2906-9 · Cited by 223 · cited 1×
“6% of the MSI (microsatellite instable) subtype (~80% of patients) and were considered key driver mutations [29,30].”
BackgroundClusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway
Killick, R., Ribe, E. M., Al-Shawi, R., Malik, B., Hooper, C., Fernandes, C., Dobson, R., Nolan, P. M., Lourdusamy, A., Furney, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.163 · Cited by 222
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09358-9 · Cited by 217
Zebisch, M., Xu, Y., Krastev, C., MacDonald, B. T., Chen, M., Gilbert, R. J. C., He, X., & Jones, E. Y. (2013) · Nature Communications · doi:10.1038/ncomms3787 · Cited by 217 · cited 1×
“This interaction prevents the RNF43/ZNFR3-mediated lysosomal degradation of FZD and maintains Wnt signaling transduction [13].”
BackgroundCommon dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
Bengochea, A., de Souza, M. M., Lefrançois, L., Le Roux, E., Galy, O., Chemin, I., Kim, M., Wands, J. R., Trepo, C., Hainaut, P., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604422 · Cited by 215 · cited 5×
“In hepatocellular carcinoma (HCC), almost 50% of mutations in the Wnt signaling pathway are activation mutations [37].”
BackgroundInfluentialSelf-citationCadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target
Yu, W., Yang, L., Li, T., & Zhang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00989 · Cited by 211 · cited 1×
“β-catenin is an armadillo repeat protein associated with the cytoplasmic domain of cadherins, cell–cell junction proteins [16,17].”
BackgroundJimeno, A., Gordon, M., Chugh, R., Messersmith, W., Mendelson, D., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Uttamsingh, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2157 · Cited by 209 · cited 5×
“A monoclonal antibody (mAB), OMP-18R5, binds to five FZD receptors (FZD1, FZD2, FZD5, FZD7, and FZD8) and blocks the canonical Wnt pathway [65].”
BackgroundInfluentialCanonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., Millar, S. E., Hoey, T., Hebrok, M., & Pasca di Magliano, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4384 · Cited by 208 · cited 1×
“Although genetic alterations in Wnt signaling are rarely detected in PDAC, many studies have suggested that the activation of Wnt signaling is involved in pancreatic tumorigenesis [42,50].”
BackgroundDiscovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled
Grandy, D., Shan, J., Zhang, X., Rao, S., Akunuru, S., Li, H., Zhang, Y., Alpatov, I., Zhang, X. A., Lang, R. A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.009647 · Cited by 201
Aartsma-Rus, A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0665 · Cited by 196
Recent Advances in Oligonucleotide Therapeutics in Oncology
Xiong, H., Veedu, R. N., & Diermeier, S. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073295 · Cited by 189
Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer
Junttila, M. R., Mao, W., Wang, X., Wang, B.-E., Pham, T., Flygare, J., Yu, S.-F., Yee, S., Goldenberg, D., Fields, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7433 · Cited by 182
Trosset, J., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianellini, L. M., Catana, C., Sundström, M., Stouten, P. F. W., et al. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20955 · Cited by 181
Rodon, J., Argilés, G., Connolly, R. M., Vaishampayan, U., de Jonge, M., Garralda, E., Giannakis, M., Smith, D. C., Dobson, J. R., McLaughlin, M. E., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01389-8 · Cited by 174 · cited 2×
“LGK974 PORCN • Metastatic Colorectal Cancer • Metastatic Head and Neck Squamous Cell Carcinoma • Solid Malignancies Phase 1/2 (NCT02278133) Phase 2 (NCT02649530) Phase 1 (NCT01351103) Canonical/ Non-canonical [3,43,54]”
BackgroundNovel Synthetic Antagonists of Canonical Wnt Signaling Inhibit Colorectal Cancer Cell Growth
Waaler, J., Machon, O., von Kries, J. P., Wilson, S. R., Lundenes, E., Wedlich, D., Gradl, D., Paulsen, J. E., Machonova, O., Dembinski, J. L., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1282 · Cited by 165
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Wagner, A. H., Devarakonda, S., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 163 · cited 3×
“PF-06647020 delivered anti-cancer drugs effectively and has shown anti-cancer effects in various cancer cell lines and PDXs (NSCLC, OVAC, and TNBC).”
BackgroundRegulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer
Rennoll, S. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.290 · Cited by 162
Inhibition of Wnt signaling by Dishevelled PDZ peptides
Zhang, Y., Appleton, B. A., Wiesmann, C., Lau, T., Costa, M., Hannoush, R. N., & Sidhu, S. S. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.152 · Cited by 161
Liao, H., Li, X., Zhao, L., Wang, Y., Wang, X., Wu, Y., Zhou, X., Fu, W., Liu, L., Hu, H.-G., et al. (2020) · Cell Discovery · doi:10.1038/s41421-020-0171-1 · Cited by 156
Diamond, J. R., Becerra, C., Richards, D., Mita, A., Osborne, C., O’Shaughnessy, J., Zhang, C., Henner, R., Kapoun, A. M., Xu, L., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05817-w · Cited by 152 · cited 1×
“OMP-18R5 FZD1/2/ 5/7/8 • Solid Tumors • Pancreatic Cancer • Metastatic Breast Cancer Phase 1 (NCT01345201) Phase 1 (NCT01957007) Phase 1 (NCT02005315) Phase 1 (NCT01973309) Canonical [64,65]”
BackgroundCaneparo, L., Huang, Y.-L., Staudt, N., Tada, M., Ahrendt, R., Kazanskaya, O., Niehrs, C., & Houart, C. (2007) · Genes & Development · doi:10.1101/gad.406007 · Cited by 150
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
Säfholm, A., Tuomela, J., Rosenkvist, J., Dejmek, J., Härkönen, P., & Andersson, T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0711 · Cited by 124
Hirata, H., Hinoda, Y., Nakajima, K., Kawamoto, K., Kikuno, N., Ueno, K., Yamamura, S., Zaman, M. S., Khatri, G., Chen, Y., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25507 · Cited by 121
de la Roche, M., Rutherford, T. J., Gupta, D., Veprintsev, D. B., Saxty, B., Freund, S. M., & Bienz, M. (2012) · Nature Communications · doi:10.1038/ncomms1680 · Cited by 120
Voronkov, A., Holsworth, D. D., Waaler, J., Wilson, S. R., Ekblad, B., Perdreau-Dahl, H., Dinh, H., Drewes, G., Hopf, C., Morth, J. P., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4000566 · Cited by 118
Shultz, M. D., Cheung, A. K., Kirby, C. A., Firestone, B., Fan, J., Chen, C. H.-T., Chen, Z., Chin, D. N., DiPietro, L., Fazal, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400807n · Cited by 118
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 117
Cowling, V. H., D'Cruz, C. M., Chodosh, L. A., & Cole, M. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02282-06 · Cited by 112
The Development of Highly Potent Inhibitors for Porcupine
Wang, X., Moon, J., Dodge, M. E., Pan, X., Zhang, L., Hanson, J. M., Tuladhar, R., Ma, Z., Shi, H., Williams, N. S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400159c · Cited by 106
A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription
Ewan, K., Pająk, B., Stubbs, M., Todd, H., Barbeau, O., Quevedo, C., Botfield, H., Young, R., Ruddle, R., Samuel, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1028 · Cited by 102
Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation
Cha, P.-H., Cho, Y.-H., Lee, S.-K., Lee, J., Jeong, W.-J., Moon, B.-S., Yun, J.-H., Yang, J. S., Choi, S., Yoon, J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2103 · Cited by 101
Self-citationSulindac Inhibits Canonical Wnt Signaling by Blocking the PDZ Domain of the Protein Dishevelled
Lee, H., Wang, N. X., Shi, D., & Zheng, J. J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200902981 · Cited by 100 · cited 2×
“Later, Sulindac exhibited inhibition of the Wnt/β-catenin pathway by binding to the PDZ domain of Dvl, blocking the destruction complex at the cell membrane [73].”
BackgroundFiskus, W., Sharma, S., Saha, S., Shah, B., Devaraj, S. G. T., Sun, B., Horrigan, S., Leveque, C., Zu, Y., Iyer, S., et al. (2015) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 98
Yuan, G., Regel, I., Lian, F., Friedrich, T., Hitkova, I., Hofheinz, R., Ströbel, P., Langer, R., Keller, G., Röcken, C., et al. (2012) · Oncogene · doi:10.1038/onc.2012.40 · Cited by 98 · cited 1×
“The overexpression of Wnt1 or a combination of prostaglandin pathways induces preneoplastic lesions or invasive gastric cancer, respectively, in mouse models [33].”
BackgroundEndo, Y., Beauchamp, E., Woods, D., Taylor, W. G., Toretsky, J. A., üren, A., & Rubin, J. S. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01780-07 · Cited by 97
Antibody Drug Conjugates as Cancer Therapeutics
Trail, P. (2013) · Antibodies · doi:10.3390/antib2010113 · Cited by 96
Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma
Nambotin, S. B., Lefrançois, L., Sainsily, X., Berthillon, P., Kim, M., Wands, J. R., Chevallier, M., Jalinot, P., Scoazec, J., TREPO, C. G., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.033 · Cited by 95
Self-citationOsawa, Y., Oboki, K., Imamura, J., Kojika, E., Hayashi, Y., Hishima, T., Saibara, T., Shibasaki, F., Kohara, M., & Kimura, K. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.10.010 · Cited by 94 · cited 5×
“ICG-001 and its analog PRI-724 interfere with the interaction between β-catenin and CBP [80,81].”
BackgroundInfluentialAPC mutations are infrequent but present in human lung cancer
Ohgaki, H. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.020 · Cited by 93 · cited 1×
“In lung cancer, the mutation of CTNNB1 and APC genes is not common [45,46].”
BackgroundTMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling
Jung, Y.-S., Jun, S., Kim, M. J., Lee, S. H., Suh, H. N., Lien, E. M., Jung, H.-Y., Lee, S., Zhang, J., Yang, J.-I., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0219-8 · Cited by 93
Self-citationMcGonigle, S., Chen, Z., Wu, J., Chang, P., Kolber, D. L., Ackermann, K. E., Twine, N. C., Shie, J., Miu, J. T., Huang, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5846 · Cited by 93 · cited 1×
“E7449 TNK1/2 • Advanced Ovarian Cancer • Advanced Solid Tumors/ • B-cell Malignancies Phase 2 (NCT03878849) Phase 1 (NCT01618136) Canonical [75,76]”
BackgroundWIKI4, a Novel Inhibitor of Tankyrase and Wnt/ß-Catenin Signaling
James, R. G., Davidson, K. C., Bosch, K. A., Biechele, T. L., Robin, N. C., Taylor, R. J., Major, M. B., Camp, N. D., Fowler, K., Martins, T. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050457 · Cited by 92
A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells
Nile, A. H., Melo, F. D. S. E., Mukund, S., Piskol, R., Hansen, S., Zhou, L., Zhang, Y., Fu, Y., Gogol, E. B., Kömüves, L. G., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0035-2 · Cited by 90
Molenaar, R. J., Coelen, R. J. S., Khurshed, M., Roos, E., Caan, M. W. A., Linde, M. E. V., Kouwenhoven, M. C. M., Bramer, J. A. M., Bovée, J. V. M. G., Mathôt, R. A. A., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014961 · Cited by 88
Lavergne, E., Hendaoui, I., Coulouarn, C., Ribault, C., Leseur, J., Eliat, P., Mebarki, S., Corlu, A., Clément, B., & Musso, O. C. (2010) · Oncogene · doi:10.1038/onc.2010.432 · Cited by 87
Shetti, D., Zhang, B., Fan, C., Mo, C., Lee, B. H., & Wei, K. (2019) · Cells · doi:10.3390/cells8080892 · Cited by 85
Li, M., Ding, X., Zhang, Y., Li, X., Zhou, H., Li, Y., Li, Y., Yang, P., Zhang, X., Hu, J., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02820-3 · Cited by 84
Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients
Zhu, G., Song, J., Chen, W., Yuan, D., Wang, W., Chen, X., Liu, H., Su, H., & Zhu, J. (2021) · Cancer Management and Research · doi:10.2147/cmar.s275172 · Cited by 83
Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13805 · Cited by 80
Plummer, R., Dua, D., Cresti, N., Drew, Y., Stephens, P., Foegh, M. L., Knudsen, S., Sachdev, P., Mistry, B., Dixit, V. S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0916-5 · Cited by 79 · cited 1×
“E7449 TNK1/2 • Advanced Ovarian Cancer • Advanced Solid Tumors/ • B-cell Malignancies Phase 2 (NCT03878849) Phase 1 (NCT01618136) Canonical [75,76]”
BackgroundKrause, U., Ryan, D. M., Clough, B. H., & Gregory, C. A. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.67 · Cited by 77
Selective Small Molecule Targeting β-Catenin Function Discovered by In Vivo Chemical Genetic Screen
Hao, J., Ao, A. S., Zhou, L., Murphy, C. K., Frist, A. Y., Keel, J., Thorne, C. A., Kim, K., Lee, E. N., & Hong, C. C. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.047 · Cited by 76
Mook, R. A., Wang, J., Ren, X.-R., Chen, M., Spasojević, I., Barak, L. S., Lyerly, H. K., & Chen, W. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.001 · Cited by 72
Wu, C., Zhuang, Y., Jiang, S., Liu, S., Zhou, J., Wu, J., Teng, Y., Xia, B., Wang, R., & Zou, X. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3480 · Cited by 70
Discovery of Tankyrase Inhibiting Flavones with Increased Potency and Isoenzyme Selectivity
Narwal, M., Koivunen, J., Haikarainen, T., Obaji, E., Legala, O. E., Venkannagari, H., Joensuu, P., Pihlajaniemi, T., & Lehtiö, L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401463y · Cited by 65
Li, B., Flaveny, C. A., Giambelli, C., Fei, D. L., Han, L., Hang, B. I., Bai, F., Pei, X.-H., Nose, V., Burlingame, O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101969 · Cited by 65
Suda, T., & Arai, F. (2008) · Cell · doi:10.1016/j.cell.2008.02.017 · Cited by 65 · cited 1×
“Additionally, Wnt signaling supporting tumor niches is essential for promoting various primary and metastatic cancers [43,44].”
BackgroundWNT and β-Catenin in Cancer: Genes and Therapy
Jackstadt, R., Hodder, M. C., & Sansom, O. J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033628 · Cited by 64 · cited 6×
“Despite the contribution of Wnt signaling to tumorigenesis being obvious and Wnt signaling inhibition having shown significant effects in preclinical models, no Wnt signalingtargeted drugs have proved clinically successful in cancer or other diseases [4,6].”
BackgroundInfluentialGiraudet, A.-L., Cassier, P. A., Iwao-Fukukawa, C., Garin, G., Badel, J.-N., Kryza, D., Chabaud, S., Gilles-Afchain, L., Clapisson, G., Desuzinges, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4544-x · Cited by 63 · cited 2×
“OTSA-101 is a mAB targeting FZD10 and is in a phase 1 clinical trial for sarcoma [66] (Table 1 and Figure 2).”
BackgroundDickkopf-1 mediated tumor suppression in human breast carcinoma cells
Mikheev, A. M., Mikheeva, S. A., Maxwell, J., Rivo, J., Rostomily, R., Swisshelm, K. L., & Zarbl, H. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9867-2 · Cited by 62
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Menon, M., Elliott, R., Bowers, L., Balan, N., Rafiq, R., Costa-Cabral, S., Munkonge, F., Trinidade, I., Porter, R., Campbell, A. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36447-4 · Cited by 60
Scarborough, H. A., Helfrich, B. A., Casás‐Selves, M., Schuller, A. G., Grosskurth, S. E., Kim, J., Tan, A. C., Chan, D. C. F., Zhang, Z., Zaberezhnyy, V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1179 · Cited by 59
Fischer, M. M., Yeung, V. P., Cattaruzza, F., Hussein, R., Yen, W.-C., Murriel, C., Evans, J. W., O’Young, G., Brunner, A. L., Wang, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15704-y · Cited by 58 · cited 2×
“OMP131R10 RSPO • Advance Relapsed Tumors (CRC) Phase 1 (NCT02482441) Canonical [52]”
BackgroundGoyal, L., Sirard, C. A., Schrag, M. L., Kagey, M. H., Eads, J. R., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Khorana, A. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1310 · Cited by 57
Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress
Marchetti, M., Resnick, L., Gamliel, E., Kesaraju, S., Weissbach, H., & Binninger, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005804 · Cited by 55
Wnt3a ligand facilitates autophagy in hippocampal neurons by modulating a novel GSK-3β-AMPK axis
Ríos, J. A., Godoy, J. A., & Inestrosa, N. C. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0227-0 · Cited by 52
Savvidou, I., Khong, T., Cuddihy, A., McLean, C., Horrigan, S., & Spencer, A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0624 · Cited by 50
Li, B., Orton, D., Neitzel, L. R., Astudillo, L., Shen, C., Long, J., Chen, X., Kirkbride, K. C., Doundoulakis, T., Guerra, M. L., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aak9916 · Cited by 50
Li, S., Lavrijsen, M., Bakker, A., Magierowski, M., Magierowska, K., Liu, P., Wang, W., Peppelenbosch, M. P., & Smits, R. (2020) · Oncogene · doi:10.1038/s41388-020-1232-5 · Cited by 50 · cited 2×
“Mutations in ZNRF3/RNF43 render cancer hypersensitive to Wnt ligands, leading to the hyperactivation of Wnt signaling and promotion of tumorigenesis [28].”
BackgroundCheng, D., Liu, J., Han, D., Zhang, G., Gao, W., Hsieh, M. H., Ng, N., Kasibhatla, S., Tompkins, C., Li, J., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00038 · Cited by 50
Lee, H., Bao, J., Miller, A., Zhang, C., Wu, J., Baday, Y. C., Guibao, C. D., Li, L., Wu, D., & Zheng, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.673202 · Cited by 49 · cited 2×
“PORCN IWP1, IWP2, IWP3, IWP4, IWP12, IWP L6, C59, GNF-6231, GNF-1331 [31,89–92] FZD1 DK-520, DK-419 [93,94] FZD5 IgG-2919 [51] FZD7 Fz7-21, RHPD-P1, SRI37892 [95–97] FZD8 1094-0205, 2124-0331, 3235-0367, NSC36784, NSC654259, IgG-2919 [98] WNT/FZD/LRP complex Salinomycin [32] DVL BMD4702, 3289-8625, J01-017a, FJ9, KY-0…”
Okada-Iwasaki, R., Takahashi, Y., Watanabe, Y., Ishida, H., Saito, J.-I., Nakai, R., & Asai, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0938 · Cited by 48
Yao, H., Ashihara, E., Strovel, J. W., Nakagawa, Y., Kuroda, J., Nagao, R., Tanaka, R., Yokota, A., Takeuchi, M., Hayashi, Y., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.41 · Cited by 48
Discovery of novel frizzled-7 inhibitors by targeting the receptor’s transmembrane domain
Zhang, W., Lü, W., Ananthan, S., Suto, M. J., & Li, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20665 · Cited by 48
Wang, W., Xu, L., Liu, P., Jairam, K., Yin, Y., Chen, K., Sprengers, D., Peppelenbosch, M. P., Pan, Q., & Smits, R. (2016) · Neoplasia · doi:10.1016/j.neo.2016.10.004 · Cited by 47 · cited 1×
“In addition to mutations in Wnt signaling, the overexpression of Wnt1 and Wnt6 has been observed in gastric cancer [31,32].”
BackgroundKim, H., Choi, S., Yoon, J., Lim, H. J., Lee, H., Choi, J., Ro, E. J., Heo, J., Lee, W., No, K. T., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505714 · Cited by 44
McWilliams, R. R., Ko, A. H., Chiorean, E. G., Kwak, E. L., Lenz, H.-J., Nadler, P. I., Wood, D. L., Fujimori, M., Morita, K., Inada, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.e15270 · Cited by 44 · cited 5×
“ICG-001 and its analog PRI-724 interfere with the interaction between β-catenin and CBP [80,81].”
BackgroundInfluentialWnt/β-catenin signaling pathway in lung cancer
Zhu, W., Wang, H., & Zhu, D. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2021.100113 · Cited by 44
Arora, S. P., Tenner, L. L., Sarantopoulos, J., Morris, J., Liu, Q., Mendez, J., Curiel, T. J., Michalek, J. E., & Mahalingam, D. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01892-6 · Cited by 43
Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
Kim, M. J., Huang, Y., & Park, J. (2020) · Cancers · doi:10.3390/cancers12123638 · Cited by 43 · cited 4×
“DKKs are composed of five types, of which dickkopf-1, DKK1, binds to LRP5/6 and was initially considered to inhibit canonical Wnt signaling [4,19,131].”
BackgroundInfluentialSelf-citationA FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
Do, M., Wu, C. C. N., Sonavane, P. R., Juarez, E. F., Adams, S., Ross, J., y Baena, A. R., Patel, C., Mesirov, J. P., Carson, D. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0548 · Cited by 42
Synthesis of Potent Dishevelled PDZ Domain Inhibitors Guided by Virtual Screening and NMR Studies
Shan, J., Zhang, X., Bao, J., Cassell, R. J., & Zheng, J. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01295.x · Cited by 39
Velasco, M. A. D., Kura, Y., Sakai, K., Hatanaka, Y., Davies, B. R., Campbell, H., Klein, S., Kim, Y. S., MacLeod, A. R., Sugimoto, K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122688 · Cited by 38
Ng, M. C. H., Tan, D. S. P., Subbiah, V., Weekes, C. D., Teneggi, V., Diermayr, V., Ethirajulu, K., Yeo, P., Chen, D., Blanchard, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2584 · Cited by 38
Phillips, C., Bhamra, I., Eagle, C., Flanagan, E., Armer, R., Jones, C. D., Bingham, M., Calcraft, P., Edmenson Cook, A., Thompson, B., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0095 · Cited by 36
Raman, S., Beilschmidt, M., To, M. D., Lin, K., Lui, F. E., Jmeian, Y., Ng, M. C. W., Fernandez, M. M., Fu, Y., Mascall, K. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817246116 · Cited by 34
de Montpréville, V., Lacroix, L., Rouleau, É., Mamodaly, M., Leclerc, J., Tutuianu, L., Planchard, D., Boulate, D., Mercier, O. M., Besse, B., et al. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151522 · Cited by 34
Zuo, W., Yang, H., Li, N., Ouyang, Y., Xu, X., & Hong, J. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01026-0 · Cited by 33 · cited 1×
“However, the hyperactivation of Wnt signaling is associated with tumor formation, relapse, and poor prognosis [35,47].”
BackgroundOptimizing Dvl PDZ domain inhibitor by exploring chemical space
Shan, J., & Zheng, J. (2008) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-008-9236-1 · Cited by 33
Katoh, M. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.11 · Cited by 33
Pyrvinium pamoate in the treatment of pinworm infection (enterobiasis) in the bome
Turner, J. A., & Johnson, P. E. (1962) · The Journal of Pediatrics · doi:10.1016/s0022-3476(62)80042-0 · Cited by 29
Cranmer, L. D., Razak, A. R. A., Ratan, R., Choy, E., George, S., Liebner, D. A., Stenehjem, D. D., & Gounder, M. M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.11523 · Cited by 28
Choi, J., Ma, S., Kim, H.-Y., Yun, J.-H., Heo, J.-N., Lee, W., Choi, K., & No, K. T. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.026 · Cited by 26
Popov, V., Jornayvaz, F. R., Akgül, E. Ö., Kanda, S., Jurczak, M. J., Zhang, D., Abulizi, A., Majumdar, S. K., Guigni, B. A., Petersen, K. F., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-271999 · Cited by 24
Edenfield, W. J., Richards, D., Vukelja, S. J., Weiss, G. J., Sirard, C. A., Landau, S. B., & Ramanathan, R. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8068 · Cited by 21 · cited 1×
“DKN-01 is a humanized antibody that binds to DKK1, inhibiting cancer progression [68].”
BackgroundYeung, P., Beviglia, L., Cancilla, B., Dee-Hoskins, C., Evans, J., Fischer, M. M., Yen, W.-C., Gurney, A. L., Lewicki, J. A., Hoey, T. C., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1907 · Cited by 20
Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling
Galli, L. M., Zebarjadi, N., Li, L., Lingappa, V. R., & Burrus, L. W. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.07.028 · Cited by 19 · cited 1×
“The extracellular transport of Wnt requires palmitoylation, a lipid modification mediated by a protein-serine O-palmitoyltransferase, porcupine (PORCN) [7].”
BackgroundKlempner, S. J., Bendell, J. C., Villaflor, V. M., Tenner, L. L., Stein, S., Naik, G. S., Sirard, C. A., Kagey, M. H., Chaney, M. F., & Strickler, J. H. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.357 · Cited by 18
Smith, D. C., Gordon, M. S., Messersmith, W. A., Chugh, R. K., Mendelson, D. S., Dupont, J., Stagg, R., Kapoun, A. M., Xu, L., Brachmann, R. K., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-b79 · Cited by 17
Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells
Bordonaro, M., & Lazarova, D. L. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5495 · Cited by 17
Zhang, H., Liu, C., Zhu, D., Zhang, Q., & Li, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01016 · Cited by 16
Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth
Wang, J., Mook, R. A., Ren, X.-R., Zhang, Q., Jing, G., Lu, M., Spasojević, I., Lyerly, H. K., Hsu, D. S., & Chen, W. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.09.016 · Cited by 13
Loaiza‐Bonilla, A., O’Hara, M. H., Redlinger, M., Damjanov, N., Teitelbaum, U. R., Vasilevskaya, I. A., Rosen, M. A., Heitjan, D. F., Amaravadi, R. K., & O'Dwyer, P. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3614 · Cited by 12
Inglis, D. J., Licari, J., Georgiou, K. R., Wittwer, N. L., Hamilton, R. W., Beaumont, D. M., Scherer, M. A., & Lavranos, T. C. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-3910 · Cited by 11 · cited 1×
“BNC101 LGR5 • Colorectal Cancer Phase 1 (NCT02726334) Canonical/ Non-canonical [67]”
Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.
Bhamra, I., Adams, N., Armer, R. E., Bingham, M. J., Mckeever, H., Phillips, C., Thompson, B., & Woodcock, S. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e14094 · Cited by 10 · cited 2×
“RXC004 caused the suppression of tumor growth in pancreatic cancer xenograft and gastric cancer PDX models [57].”
BackgroundMethodEads, J. R., Goyal, L., Stein, S., El-Khoueiry, A. B., Manji, G. A., Abrams, T. A., Landau, S. B., & Sirard, C. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.e15603 · Cited by 10
Scott, A., Call, J. A., Chandana, S., Borazanci, E. H., Falchook, G. S., Bordoni, R. E., Richey, S., Starodub, A., Chung, V., Lakhani, N. J., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.580 · Cited by 8 · cited 1×
“SM08502 CLK • Advanced Solid Tumors • Solid Tumor Phase 1 (NCT05084859) Phase 1 (NCT03355066) Canonical [82]”
BackgroundArend, R. C., Castro, C. M., Matulonis, U. A., Hamilton, E. P., Gunderson, C. C., Lybarger, K., Goodman, H. M., Duska, L., Mahdi, H., ElNaggar, A. C., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.06.010 · Cited by 3
Kelly, J., Woodcock, S. A., Bhamra, I., Jones, C., Armer, R. E., Robertson, J. D., & Phillips, C. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-2566 · Cited by 2
(1999) · doi:10.1002/(sici)1521-1878(199912)22:1<1021::aid-bies6>3.0.co;2-p · cited 1×
“β-catenin is an armadillo repeat protein associated with the cytoplasmic domain of cadherins, cell–cell junction proteins [16,17].”
Background
Cited by
Current advances and development strategies of orally bioavailable PROTACs
Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 91
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Additionally, recently developed technologies are currently being explored to inhibit Wnt signaling, such as proteolysis-targeting chimeras and molecular glue degraders, antibody–drug conjugates, and antisense oligonucleotides [195].”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Multiple agents targeting both canonical and the β -catenin-independent non-canonical Wnt signaling including v-ATPase inhibitors and anti-RSPO antibody are undergoing clinical trials in CRC and other malignancies [119,120].”
BackgroundLi, C., Furth, E. E., Rustgi, A. K., & Klein, P. S. (2023) · Cells · doi:10.3390/cells12182256 · Cited by 33
Structural and Functional Insights into Dishevelled-Mediated Wnt Signaling
Wang, L., Zhu, R., Wen, Z., Fan, H., Norwood-Jackson, T., Jathan, D., & Lee, H. (2024) · Cells · doi:10.3390/cells13221870 · Cited by 25
Metadata
- Authors
- Park, W.-J., & Kim, M. J.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Kim, Moon Jong
- ORCID
- Kim, Moon Jong
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-04-08
- Volume
- 12
- Issue
- 8
- Pages
- 1110
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10136927
- OpenAlex
- W4363648015
- Cited by
- 57
- References
- 188
- Citations by year
- 2026: 18 · 2025: 13 · 2024: 20 · 2023: 6
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gachon University (GCU-202110420001, NRF-2022R1F1A1074582)
- Korean government (MSIT) (GCU-202110420001, NRF-2022R1F1A1074582)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- Wnt signaling, undruggable targets, cancer therapy, Wnt inhibitors, PROTACs, molecular glues, antibody-drug conjugates, antisense oligonucleotides, clinical trials
- MeSH terms
- Cell Transformation, Neoplastic, Humans, Neoplasms, Stem Cells, Wnt Signaling Pathway, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.